Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer

被引:46
|
作者
Kantoff, PW
Halabi, S
Farmer, DA
Hayes, DF
Vogelzang, NA
Small, EJ
机构
[1] Dana Farber Canc Inst, Dept Adult Oncol, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[2] Duke Univ, Med Ctr, Ctr Stat, Canc & Leukemia Grp B, Durham, NC USA
[3] Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA
[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[5] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
关键词
D O I
10.1200/JCO.2001.19.12.3025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the prognostic significance of reverse transcriptase polymerase chain reaction (RT-PCR) detection of prostate-specific antigen (PSA) mRNA in the blood of men with hormone-refractory prostate cancer (HRPC). Patients and Methods: Peripheral blood was obtained from 193 men enrolled on Cancer and Leukemia Group B Study 9480, a prospective randomized comparison of three doses of suramin. RNA was isolated from the samples and assayed for the presence of PSA transcripts by RT-PCR. Results: RNA could be isolated in 156 (83%) of samples. PSA transcripts as measured by RT-PCR were detectable in 75 (48%) of the 156 patients. The median survival far those patients in whom no transcripts were detectable was 18 months (95% confidence interval [CI], 14 to 22 months) compared with 13 months (95% CI, 11 to 15 months) (P = .004) for those in whom transcripts were detectable. In a multivariate analysis in which other factors predictive of survival were used, RT-PCR for PSA provided independent prognostic information. Conclusion: RT-PCR for PSA predicts survival duration in a population of men with HRPC. J Clin Oncol 19:3025-3028. (C) 2001 by American Society of Clinical Oncology.
引用
收藏
页码:3025 / 3028
页数:4
相关论文
共 50 条